- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07950878
Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD PROM)
Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.
The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).
Descripción general del estudio
Descripción detallada
The first primary objective of this study is to assess the quality of life of children affected by autosomal recessive polycystic kidney disease (ARPKD) and their parents, using validated survey instruments.
The second primary objective is to determine priorities of patients, caregivers, and healthcare professionals regarding outcome measures in order to determine a set of core outcomes for future ARPKD-related clinical trials The secondary aim is to validate the use of existing quality of life questionnaire for this cohort of children with ARPKD and to compare their hrQoL to previously published cohorts of children with all-cause chronic kidney disease.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jasmine Jaber
- Número de teléfono: 267-425-5325
- Correo electrónico: jaberj2@chop.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19146
- Reclutamiento
- Children's Hospital of Philadelphia
-
Contacto:
- Jasmine Jaber
- Número de teléfono: 267-425-5325
- Correo electrónico: jaberj2@chop.edu
-
Investigador principal:
- Lisa Guay-Woodford, M.D.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Subjects should be between 0-25 years of age and have an ICD-10 diagnosis code for ARPKD in the CHOP Epic EHR.
Descripción
Inclusion Criteria:
- Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.
Exclusion Criteria:
- Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.
Lack of written informed consent. Subjects that choose not to have their responses recorded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: FAMILY_BASED
- Perspectivas temporales: OTHER
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Patients with ARPKD and their caregivers
|
Families will be asked to fill out a series of questionnaires |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PedsQL ESRD Questionnaire
Periodo de tiempo: 5 years
|
PedsQL ESRD Module (quality of life in children with end-stage renal disease) validated questionnaire on health-related QOL for children ≥ 24 months and adults < 25 years with renal disease. 35 questions. Ranking scale (not at all, sometimes, a lot). Items are reverse-scored and linearly transformed to a 0 to 100 scale, where higher scores indicate a better quality of life. |
5 years
|
|
SDQ (strength and difficulties questionnaire)
Periodo de tiempo: 5 years
|
validated brief emotional and behavioral screening tool. 38 questions. Ranking scale (not true, somewhat true, certainly true). Items divided into five scales of five items each, scored from 0 to 10 per scale, with four problem scales summed into a Total Difficulties score from 0 to 40. Higher scores indicate greater difficulty. |
5 years
|
|
IFS (impact on family scale)
Periodo de tiempo: 5 years
|
Caregiver burden will be captured by recording the burden on family life with the "Impact on Family Scale"(IFS). 35 questions. Ranking scale (strongly agree, agree, disagree, strongly disagree). Scored by rating each item on a 4-point Likert scale and summing the items to get a total score, where higher scores indicate a greater perceived impact of a child's health condition or disability on the family. |
5 years
|
|
ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children)
Periodo de tiempo: 5 years
|
Caregiver burden will be captured by recording the burden on family life with ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children). 29 questions. Ranking scale (never, rarely, sometimes, often, always). 5-point rating scale (0 = "never" to 4 = "always") based on the past 7 days, where higher scores indicate better parental quality of life. |
5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lisa Guay-Woodford, M.D., CHOP
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Ciliopatías
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades Genéticas Congénitas
- Anomalías congénitas
- Anomalías Múltiples
- Enfermedades Renales Quísticas
- Enfermedades renales poliquísticas
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Riñón poliquístico, autosómico recesivo
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Recopilación de datos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Encuestas y cuestionarios
Otros números de identificación del estudio
- 24-022381
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .